New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
08:25 EDTPTLA, BAYRY, JNJPortola Pharmaceuticals begins enrollment in Phase 3 study for Xarelto
Portola Pharmaceuticals (PTLA) announced that enrollment has begun in a Phase 3 study to evaluate the safety and efficacy of andexanet alfa, the company's investigational recombinant Factor Xa inhibitor reversal agent, with Bayer (BAYRY) and Janssen Pharmaceuticals' (JNJ) Factor Xa inhibitor XARELTO. Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class agent to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery.
News For PTLA;BAYRY;JNJ From The Last 14 Days
Check below for free stories on PTLA;BAYRY;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
07:35 EDTBAYRYZoetis seen as potential Bayer target after split announcement, Bloomberg says
Subscribe for More Information
September 18, 2014
09:43 EDTPTLASummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen discusses Portola Pharmaceuticals' Andexanet Alfa for reversing Factor Xa Inhibitors on an Analyst/Industry conference call to be held on September 18 at 11 am.
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information
September 17, 2014
17:44 EDTBAYRYBayer plans separation of MaterialsSciences unit, WSJ says
Subscribe for More Information
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information
September 16, 2014
07:31 EDTBAYRY, JNJEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
07:27 EDTJNJIBC Life Sciences to hold a conference
Subscribe for More Information
September 11, 2014
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
September 10, 2014
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information
September 8, 2014
07:15 EDTBAYRYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use